投入 2100 萬歐元用於對抗非洲腹瀉疾病
New €21 million investment to fight diarrheal diseases in Africa
Updated at: June 9, 2026 at 01:00 PM
截至2026年6月，全球衛生EDCTP3已啟動一項總額達2100萬歐元的重要投資，旨在對抗撒哈拉以南非洲的腹瀉疾病。
As of June 2026, the Global Health EDCTP3 has launched a major €21 million investment to fight diarrheal diseases in sub-Saharan Africa.
此計畫支持四項創新專案——CARE-Africa、PRoRota、HUNADIA與TARGET，目標在於改善氣候變遷、營養不良及衛生條件惡劣等因素所導致的風險地區之健康成果。
This initiative supports four innovative projects—CARE-Africa, PRoRota, HUNADIA, and TARGET—aimed at improving health outcomes in a region facing increased risks from climate change, malnutrition, and poor sanitation.
腹瀉疾病仍是五歲以下兒童死亡的主因，每年奪走數百萬條生命。
Diarrheal diseases remain a leading cause of death for children under five, claiming millions of lives annually.
氣候變遷使此危機更趨複雜，氣溫升高與洪患與更頻繁且難以預測的疫情爆發有關。
Climate change further complicates this crisis, with rising temperatures and flooding linked to more frequent, unpredictable outbreaks.
這筆資金將支持後期臨床研究並強化醫療體系。
The funding will support late-stage clinical research and strengthen health systems.
其他專案，如TARGET，則專注於治療肯亞與坦尚尼亞的營養不良兒童。
Other projects, like TARGET, focus specifically on treating malnourished children in Kenya and Tanzania.
透過將先進技術與跨國大規模臨床試驗結合，此項投資標誌著保護脆弱族群並在非洲大陸建立更具韌性醫療基礎設施的重要一步。
By combining advanced technology with large-scale clinical trials across multiple countries, this investment marks a vital step toward protecting vulnerable populations and building more resilient health infrastructure across the African continent.
